Public Policy Resources

Share

Partner Letter to FDA on Tobacco Product Applications for JUUL

April 27, 2021

As you are aware, the Center for Tobacco Products (CTP) at the Food and Drug Administration (FDA) is reviewing Premarket Tobacco Product Applications (PMTAs) for e-cigarettes and other new tobacco products on the market as of the effective date of the deeming rule (August 8, 2016). In his “Perspective: FDA’s Progress on Review of Tobacco Product Applications Submitted by the Sept. 9, 2020 Deadline,” (FDA Progress Report), issued February 16, 2021, CTP Director Mitch Zeller makes it clear that the products accounting for the greatest market share will receive “first review.” According to the FDA Progress Report, this expedited treatment is justified because “[t]he continued marketing of these products has the potential to have the greatest public health impact – either positively or negatively – as they hold the largest overall market share and therefore likely used by the largest number of people.”

Because JUUL’s products continue to have the largest share of the e-cigarette market, and therefore presumably are undergoing expedited review, we write at this time to express our conclusion that based on all of the publicly available evidence, no JUUL product currently on the market can meet the statutory public health standard. Therefore, they should not receive a marketing order.

PDF icon Letter on JUUL PMTA 4-27-21.pdf

Related Resources

November 8, 2024

History of the Racketeering Lawsuit Against the Tobacco Industry: Guilty of Deceiving the American Public

In 1999, the U.S. Department of Justice (DOJ) filed a lawsuit against major tobacco manufacturers Philip Morris USA, R.J. Reynolds Tobacco, Lorillard, and Altria to hold the industry accountable for more than 50 years of conspiring to defraud the public in violation of the Racketeer Influenced and Corrupt Organizations (RICO) Act. Big Tobacco, an industry which has for decades knowingly addicted and endangered the lives of millions of Americans for their own profit, must now post the truth about their deadly products, including at the point-of-sale (POS) for approximately 220,000 tobacco retailers.

Read More

ACS CAN & Federal Tobacco Litigation - An Overview

October 25, 2024

The tobacco industry has a history of using litigation to avoid and delay laws and regulations enacted to safeguard the public. ACS CAN, with our tobacco control partners, has also relied on the courts to hold Big Tobacco accountable and to ensure the federal government is effectively implementing the Tobacco Control Act.

Read more

Delayed Implementation of Graphic Warning Labels on Cigarettes Harms Public Health

October 25, 2024

Implementation of graphic warnings in the U.S. has been thwarted by tobacco industry legal challenges. The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN), along with our partners, have fought back in the judicial system, using litigation to both compel the U.S. Food and Drug Administration (FDA) to issue graphic warning regulations and help the U.S. Department of Justice (DOJ) defend the regulations finalized by FDA.

Read more